文献类型：期刊文献

英文题名：Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a meta-analysis

作者：Lv, Xinfang[1,2,3,4];Pan, ChenLiang[5];Guo, Huan[6];Chang, Juan[7];Gao, Xiang[1,2,3];Wu, Xue[1,2];Zhi, Xiaodong[1,2,3];Ren, Chunzhen[1,2];Chen, Qilin[1,2];Jiang, Hugang[1,2];Zhao, Xinke[1,2,3,8];Liu, Kai[1,2,3];Li, Yingdong[1,2,3]

第一作者：Lv, Xinfang

通信作者：Zhao, XK[1];Liu, K[1];Li, YD[1];Zhao, XK[2]

机构：[1]Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China;[2]Univ Hosp Gansu Tradit Chinese Med, Key Lab Prevent & Treatment Chron Dis Tradit Chine, Lanzhou, Peoples R China;[3]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou, Peoples R China;[4]Res Ctr Tradit Chinese Med, Lanzhou, Peoples R China;[5]Lanzhou Univ, Hosp 1, Lanzhou, Peoples R China;[6]Gansu Prov Acad Inst Med Res, Lanzhou, Peoples R China;[7]Gansu Prov Hosp, Lanzhou, Peoples R China;[8]Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou 730000, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Lanzhou 730000, Peoples R China;[2]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, Lanzhou 730000, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;

年份：2023

卷号：10

期号：4

起止页码：2170

外文期刊名：ESC HEART FAILURE

收录：;Scopus(收录号：2-s2.0-85159045367);WOS:【SCI-EXPANDED(收录号:WOS:000985149400001)】；

语种：英文

外文关键词：Cardio-oncology; Cardiac dysfunction; Cardiotoxicity; High-sensitivity cardiac troponin T; Early diagnosis; Meta-analysis

摘要：Early diagnosis of cancer treatment-related cardiac dysfunction (CTRCD) is important as cancer therapy increases the risk of cardiac dysfunction. High-sensitivity cardiac troponin T (hs-cTnT) is a highly specific marker of myocardial injury. However, its diagnostic value for CTRCD has not been systematically evaluated. This meta-analysis aimed to evaluate whether hs-cTnT could be used as an early diagnostic biomarker for CTRCD. We systematically surveyed PubMed, Embase, Cochrane Library, and Web of Science databases for studies of hs-cTnT for the diagnosis of CTRCD before 1 April 2022. Patients of all ages and all cancer types who underwent echocardiographic left ventricular ejection fraction assessment and blood hs-cTnT and received anticancer therapy (including chemotherapy, radiotherapy, targeted therapy, immune checkpoint inhibitors, and other treatments) were included in this study, resulting in a total of eight studies with 1294 patients. The occurrence of CTRCD was associated with elevated hs-cTnT [sensitivity: 0.78, 95% confidence interval (CI): 0.64-0.88; specificity: 0.75, 95% CI: 0.59-0.86; area under the curve (AUC): 0.83, 95% CI: 0.80-0.86]. We further performed subgroup analysis and found that the AUC of hs-cTnT elevation for the diagnosis of CTRCD increased from 0.83 to 0.90 (95% CI: 0.87-0.92) at 3-6 months, suggesting a higher early diagnostic value of hs-cTnT compared with echocardiography for CTRCD. In terms of clinical applicability, the Fagan plot showed pre-test and post-test probabilities of 51% and 9%, respectively, indicating that hs-cTnT testing can improve the accuracy of clinical diagnosis of CTRCD. However, it was not possible to determine the optimal cut-off value for early diagnosis of CTRCD with hs-cTnT. The Deeks funnel plot was largely symmetrical (P = 0.74); hence, publication bias was not observed. Hs-cTnT allowed early CTRCD diagnosis at 3-6 months. However, further high-quality research is needed to determine the optimal cut-off value for early CTRCD diagnosis with this biomarker.